DAX+1,36 % EUR/USD-0,03 % Gold+0,02 % Öl (Brent)+0,42 %

DGAP-Ad hoc: november AG english = - 500 Beiträge pro Seite



Beitrag schreiben

Begriffe und/oder Benutzer

 

Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------------

november AG acquires nearly 25 percent of ACGT ProGenomics AG Research capacities significantly expanded / share deal Erlangen, 14 August 2001. Within the scope of a share deal, the Erlangen/Germany-based november AG takes over a stake of 24.95 percent in ACGT ProGenomics AG, Halle (Saale)/Germany. Especially in the field of Molecular Therapy, the biotechnology company which is listed at the Neuer Markt (symbol nbx) gains access to important property rights and developments that add to its own portfolio and are synergistic to own approaches. This enables november AG to significantly expand its research capacities and its development potential without affecting liquidity. At the same time, november AG receives the option to further strengthen the partnership, for example by future capital measures. Through this transaction, both companies intensify their strategic co- operation. november is already the exclusive licensee for ACGT ProGenomics` TmHU, a protein that can be used in biotechnological research for transporting bio-molecules into cells. november and ACGT ProGenomics plan to jointly develop additional therapeutical drug delivery systems. The participation will be fulfilled on november`s and ACGT ProGenomics` side via increase of capital stock. ACGT ProGenomics increases its subscribed capital to an extent that enables november AG to hold a 24.95 percent stake. november AG issues 240,000 new shares from its authorised capital for this share. The subscribed capital of november AG hence rises to Euro 6.81 million. ACGT ProGenomics was founded in 2000. In the field of therapeutics, the research and development company develops novel drug delivery systems and in the field of diagnostics a sensitive and cost-efficient method for early-stage diagnosis of diseases such as Alzheimer and BSE. This results in direct synergies to november AG`s fields of research and development. For further information: november AG: Christian Fenner, Tel.: +49 (0)9131-75088-870, Fax: +49 (0) 9131- 750888-99, e-Mail: ir@november.de

ACGT ProGenomics AG: Dr. Gerald Böhm, Tel.: +49 (0)345-5559-955 Fax: +49 (0)345-5559-755, e-Mail: info@acgt-progenomics.de

end of ad hoc announcement (c) DGAP 14.08.2001 -------------------------------------------------------------------------------- WKN: 676290; Index: Listed: Neuer Markt Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, München, Hannover und Stuttgart

140800 Aug 01



Autor: DGAP import (),08:04 14.08.2001



Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um einen ältere Diskussionen, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier ein neue Diskussion.